SNDL Valuation

Is SNDL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • PM vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SNDL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SNDL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SNDL's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SNDL?

Other financial metrics that can be useful for relative valuation.

SNDL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.5x
Enterprise Value/EBITDA-4.9x
PEG Ration/a

Price to Sales Ratio vs Peers

How does SNDL's PS Ratio compare to its peers?

The above table shows the PS ratio for SNDL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.6x
XERS Xeris Biopharma Holdings
2.8x15.5%US$429.6m
RVNC Revance Therapeutics
2.3x23.7%US$499.7m
MRNS Marinus Pharmaceuticals
17.6x44.9%US$545.2m
HROW Harrow
3.6x25.0%US$395.8m
SNDL SNDL
0.6x9.7%US$354.3m

Price-To-Sales vs Peers: SNDL is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (6.6x).


Price to Earnings Ratio vs Industry

How does SNDL's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a21.1%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a21.1%
n/an/an/a
No more companies

Price-To-Sales vs Industry: SNDL is good value based on its Price-To-Sales Ratio (0.6x) compared to the US Pharmaceuticals industry average (3.1x).


Price to Sales Ratio vs Fair Ratio

What is SNDL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SNDL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.6x
Fair PS Ratio1.9x

PM vs Fair Ratio: SNDL is good value based on its Price-To-Sales Ratio (0.6x) compared to the estimated Fair Price-To-Sales Ratio (1.9x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SNDL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.43
US$3.65
+156.0%
9.7%US$4.00US$3.30n/a2
Feb ’25US$1.39
US$3.65
+162.4%
9.7%US$4.00US$3.30n/a2
Jan ’25US$1.64
US$3.65
+122.4%
9.7%US$4.00US$3.30n/a2
Dec ’24US$1.50
US$3.64
+142.8%
10.2%US$4.01US$3.27n/a2
Jun ’24US$1.45
US$3.26
+125.1%
0.6%US$3.28US$3.24n/a2
May ’24US$1.54
US$3.27
+112.2%
0.02%US$3.27US$3.27n/a2
Apr ’24US$1.60
US$3.45
+115.6%
11.0%US$3.98US$2.95n/a4
Mar ’24US$1.82
US$3.45
+89.5%
11.0%US$3.98US$2.95n/a4
Feb ’24US$2.33
US$3.45
+48.0%
11.0%US$3.98US$2.95US$1.394
Jan ’24US$2.09
US$3.42
+63.6%
10.9%US$3.94US$2.93US$1.644
Dec ’23US$2.88
US$3.43
+18.9%
11.3%US$3.97US$2.95US$1.504
Nov ’23US$2.41
US$3.39
+40.5%
14.4%US$4.00US$2.81US$1.443
Oct ’23US$2.18
US$4.20
+92.6%
27.2%US$6.02US$2.98US$1.904
Sep ’23US$2.72
US$4.20
+54.4%
27.2%US$6.02US$2.98US$1.764
Aug ’23US$2.28
US$5.72
+150.8%
23.5%US$8.04US$4.84US$1.604
Jul ’23US$3.33
US$5.69
+71.0%
23.9%US$8.04US$4.80US$1.374
Jun ’23US$3.75
US$5.75
+53.3%
22.7%US$8.00US$4.87US$1.454
May ’23US$4.69
US$7.64
+62.8%
17.5%US$9.45US$5.85US$1.546
Apr ’23US$7.00
US$8.12
+16.0%
14.1%US$9.70US$6.00US$1.606
Mar ’23US$5.06
US$7.92
+56.8%
20.2%US$9.67US$4.99US$1.825
Feb ’23US$4.92
US$7.92
+61.0%
20.2%US$9.67US$4.99US$2.335

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.